Cargando…

1001. Feasibility and Outcomes of a Pre-Transplant Antibiotic Allergy Evaluation Program for Allogeneic Hematopoietic Cell Transplant (HCT) Candidates

BACKGROUND: Antibiotic allergies impact the management of hematopoietic cell transplant (HCT) patients who are often prescribed antibiotics for infection prophylaxis and treatment. We evaluated the feasibility and outcomes of an antibiotic allergy evaluation program prior to allogeneic HCT. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Catherine, Krantz, Elizabeth M, Stohs, Erica J, Imlay, Hannah, Rampur, Lahari, Sweet, Ania, Zier, Jacqlynn C, Pergam, Steven A, Mielcarek, Marco, Henderson, William, Altman, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811251/
http://dx.doi.org/10.1093/ofid/ofz360.865
_version_ 1783462436542611456
author Liu, Catherine
Krantz, Elizabeth M
Stohs, Erica J
Imlay, Hannah
Rampur, Lahari
Sweet, Ania
Zier, Jacqlynn C
Pergam, Steven A
Mielcarek, Marco
Henderson, William
Altman, Matthew
author_facet Liu, Catherine
Krantz, Elizabeth M
Stohs, Erica J
Imlay, Hannah
Rampur, Lahari
Sweet, Ania
Zier, Jacqlynn C
Pergam, Steven A
Mielcarek, Marco
Henderson, William
Altman, Matthew
author_sort Liu, Catherine
collection PubMed
description BACKGROUND: Antibiotic allergies impact the management of hematopoietic cell transplant (HCT) patients who are often prescribed antibiotics for infection prophylaxis and treatment. We evaluated the feasibility and outcomes of an antibiotic allergy evaluation program prior to allogeneic HCT. METHODS: In August 2017, we implemented a program to expedite allergy clinic referrals for adult allogeneic HCT candidates who reported an antibiotic allergy at their initial pre-transplant evaluation visit (PTEV). Allergy labels and clinical data including outcomes of allergy evaluation were prospectively collected for patients with PTEVs between 8/10/17 and November 15/18. The use of selected antibiotics was collected in the 100 days following HCT among patients with a reported β-lactam allergy (BLA). Choice of prophylactic agent for Pneumocystis jiroveci among patients with reported sulfa allergies was assessed among HCT recipients after engraftment. RESULTS: Of 276 allogeneic HCT candidates, 109 (39.5%) reported >= 1 antibiotic allergy (Table 1). Of the 109, 69 (63%) were referred for allergy evaluation; 83% (57/69) of those referred were evaluated at a median of 14 days after PTEV, and a median of 18 days before transplant. Among evaluated patients, 45 (79%) had >= 1 antibiotic allergy de-labeled including 74% (28/38) of those with BLA (Figure 1). Of the 10 patients whose BLAs could not be delabeled, 1 had a possible immediate IgE-mediated reaction, 5 had a delayed type IV hypersensitivity, and 4 had other reactions or required additional testing. Post-transplant antibiotic use among evaluated vs. nonevaluated patients reporting BLA is shown in Figure 2. Among 31 patients with reported sulfa allergies who underwent HCT, those who were evaluated received TMP-SMX rather than alternative prophylaxis more often (48%; 11/23) than those who were not evaluated (25%; 2/8). 10 (43%) of 23 evaluated patients were delabeled; 7 of 10 delabeled patients received TMP-SMX. CONCLUSION: Antibiotic allergies are frequently reported among HCT candidates. Pre-transplant antibiotic allergy evaluation was feasible, led to de-labeling of the majority of reported allergies, and may alter antibiotic prescribing and increase the use of preferred agents following transplant. [Image: see text] [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6811251
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68112512019-10-29 1001. Feasibility and Outcomes of a Pre-Transplant Antibiotic Allergy Evaluation Program for Allogeneic Hematopoietic Cell Transplant (HCT) Candidates Liu, Catherine Krantz, Elizabeth M Stohs, Erica J Imlay, Hannah Rampur, Lahari Sweet, Ania Zier, Jacqlynn C Pergam, Steven A Mielcarek, Marco Henderson, William Altman, Matthew Open Forum Infect Dis Abstracts BACKGROUND: Antibiotic allergies impact the management of hematopoietic cell transplant (HCT) patients who are often prescribed antibiotics for infection prophylaxis and treatment. We evaluated the feasibility and outcomes of an antibiotic allergy evaluation program prior to allogeneic HCT. METHODS: In August 2017, we implemented a program to expedite allergy clinic referrals for adult allogeneic HCT candidates who reported an antibiotic allergy at their initial pre-transplant evaluation visit (PTEV). Allergy labels and clinical data including outcomes of allergy evaluation were prospectively collected for patients with PTEVs between 8/10/17 and November 15/18. The use of selected antibiotics was collected in the 100 days following HCT among patients with a reported β-lactam allergy (BLA). Choice of prophylactic agent for Pneumocystis jiroveci among patients with reported sulfa allergies was assessed among HCT recipients after engraftment. RESULTS: Of 276 allogeneic HCT candidates, 109 (39.5%) reported >= 1 antibiotic allergy (Table 1). Of the 109, 69 (63%) were referred for allergy evaluation; 83% (57/69) of those referred were evaluated at a median of 14 days after PTEV, and a median of 18 days before transplant. Among evaluated patients, 45 (79%) had >= 1 antibiotic allergy de-labeled including 74% (28/38) of those with BLA (Figure 1). Of the 10 patients whose BLAs could not be delabeled, 1 had a possible immediate IgE-mediated reaction, 5 had a delayed type IV hypersensitivity, and 4 had other reactions or required additional testing. Post-transplant antibiotic use among evaluated vs. nonevaluated patients reporting BLA is shown in Figure 2. Among 31 patients with reported sulfa allergies who underwent HCT, those who were evaluated received TMP-SMX rather than alternative prophylaxis more often (48%; 11/23) than those who were not evaluated (25%; 2/8). 10 (43%) of 23 evaluated patients were delabeled; 7 of 10 delabeled patients received TMP-SMX. CONCLUSION: Antibiotic allergies are frequently reported among HCT candidates. Pre-transplant antibiotic allergy evaluation was feasible, led to de-labeling of the majority of reported allergies, and may alter antibiotic prescribing and increase the use of preferred agents following transplant. [Image: see text] [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6811251/ http://dx.doi.org/10.1093/ofid/ofz360.865 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Liu, Catherine
Krantz, Elizabeth M
Stohs, Erica J
Imlay, Hannah
Rampur, Lahari
Sweet, Ania
Zier, Jacqlynn C
Pergam, Steven A
Mielcarek, Marco
Henderson, William
Altman, Matthew
1001. Feasibility and Outcomes of a Pre-Transplant Antibiotic Allergy Evaluation Program for Allogeneic Hematopoietic Cell Transplant (HCT) Candidates
title 1001. Feasibility and Outcomes of a Pre-Transplant Antibiotic Allergy Evaluation Program for Allogeneic Hematopoietic Cell Transplant (HCT) Candidates
title_full 1001. Feasibility and Outcomes of a Pre-Transplant Antibiotic Allergy Evaluation Program for Allogeneic Hematopoietic Cell Transplant (HCT) Candidates
title_fullStr 1001. Feasibility and Outcomes of a Pre-Transplant Antibiotic Allergy Evaluation Program for Allogeneic Hematopoietic Cell Transplant (HCT) Candidates
title_full_unstemmed 1001. Feasibility and Outcomes of a Pre-Transplant Antibiotic Allergy Evaluation Program for Allogeneic Hematopoietic Cell Transplant (HCT) Candidates
title_short 1001. Feasibility and Outcomes of a Pre-Transplant Antibiotic Allergy Evaluation Program for Allogeneic Hematopoietic Cell Transplant (HCT) Candidates
title_sort 1001. feasibility and outcomes of a pre-transplant antibiotic allergy evaluation program for allogeneic hematopoietic cell transplant (hct) candidates
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811251/
http://dx.doi.org/10.1093/ofid/ofz360.865
work_keys_str_mv AT liucatherine 1001feasibilityandoutcomesofapretransplantantibioticallergyevaluationprogramforallogeneichematopoieticcelltransplanthctcandidates
AT krantzelizabethm 1001feasibilityandoutcomesofapretransplantantibioticallergyevaluationprogramforallogeneichematopoieticcelltransplanthctcandidates
AT stohsericaj 1001feasibilityandoutcomesofapretransplantantibioticallergyevaluationprogramforallogeneichematopoieticcelltransplanthctcandidates
AT imlayhannah 1001feasibilityandoutcomesofapretransplantantibioticallergyevaluationprogramforallogeneichematopoieticcelltransplanthctcandidates
AT rampurlahari 1001feasibilityandoutcomesofapretransplantantibioticallergyevaluationprogramforallogeneichematopoieticcelltransplanthctcandidates
AT sweetania 1001feasibilityandoutcomesofapretransplantantibioticallergyevaluationprogramforallogeneichematopoieticcelltransplanthctcandidates
AT zierjacqlynnc 1001feasibilityandoutcomesofapretransplantantibioticallergyevaluationprogramforallogeneichematopoieticcelltransplanthctcandidates
AT pergamstevena 1001feasibilityandoutcomesofapretransplantantibioticallergyevaluationprogramforallogeneichematopoieticcelltransplanthctcandidates
AT mielcarekmarco 1001feasibilityandoutcomesofapretransplantantibioticallergyevaluationprogramforallogeneichematopoieticcelltransplanthctcandidates
AT hendersonwilliam 1001feasibilityandoutcomesofapretransplantantibioticallergyevaluationprogramforallogeneichematopoieticcelltransplanthctcandidates
AT altmanmatthew 1001feasibilityandoutcomesofapretransplantantibioticallergyevaluationprogramforallogeneichematopoieticcelltransplanthctcandidates